IL212309A - Compositions for use in treating matrix metalloproteinase 9 (mmp9)-mediated conditions - Google Patents

Compositions for use in treating matrix metalloproteinase 9 (mmp9)-mediated conditions

Info

Publication number
IL212309A
IL212309A IL212309A IL21230911A IL212309A IL 212309 A IL212309 A IL 212309A IL 212309 A IL212309 A IL 212309A IL 21230911 A IL21230911 A IL 21230911A IL 212309 A IL212309 A IL 212309A
Authority
IL
Israel
Prior art keywords
mmp9
compositions
matrix metalloproteinase
mediated conditions
treating matrix
Prior art date
Application number
IL212309A
Other languages
Hebrew (he)
Other versions
IL212309A0 (en
Original Assignee
Revalesio Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/258,210 external-priority patent/US20090274730A1/en
Application filed by Revalesio Corp filed Critical Revalesio Corp
Publication of IL212309A0 publication Critical patent/IL212309A0/en
Publication of IL212309A publication Critical patent/IL212309A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
IL212309A 2008-10-22 2011-04-13 Compositions for use in treating matrix metalloproteinase 9 (mmp9)-mediated conditions IL212309A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10745308P 2008-10-22 2008-10-22
US10748008P 2008-10-22 2008-10-22
US12/258,210 US20090274730A1 (en) 2007-10-25 2008-10-24 Compositions and methods for treating inflammation
PCT/US2009/061744 WO2010048455A1 (en) 2008-10-22 2009-10-22 Compositions and methods for treating matrix metalloproteinase 9 (mmp9)-mediated conditions

Publications (2)

Publication Number Publication Date
IL212309A0 IL212309A0 (en) 2011-06-30
IL212309A true IL212309A (en) 2016-04-21

Family

ID=42119683

Family Applications (2)

Application Number Title Priority Date Filing Date
IL212277A IL212277A0 (en) 2008-10-22 2011-04-12 Compositions for use in treating thymic stromal lymphopoietin (tslp)-mediated conditions
IL212309A IL212309A (en) 2008-10-22 2011-04-13 Compositions for use in treating matrix metalloproteinase 9 (mmp9)-mediated conditions

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL212277A IL212277A0 (en) 2008-10-22 2011-04-12 Compositions for use in treating thymic stromal lymphopoietin (tslp)-mediated conditions

Country Status (9)

Country Link
EP (2) EP2364154A4 (en)
JP (4) JP5688370B2 (en)
CN (2) CN102257130B (en)
AU (2) AU2009308302B2 (en)
BR (2) BRPI0920430A2 (en)
CA (2) CA2741341A1 (en)
IL (2) IL212277A0 (en)
MX (2) MX2011004233A (en)
WO (2) WO2010048425A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6702949B2 (en) 1997-10-24 2004-03-09 Microdiffusion, Inc. Diffuser/emulsifier for aquaculture applications
US8597689B2 (en) 2006-10-25 2013-12-03 Revalesio Corporation Methods of wound care and treatment
US7832920B2 (en) 2006-10-25 2010-11-16 Revalesio Corporation Mixing device for creating an output mixture by mixing a first material and a second material
US8445546B2 (en) 2006-10-25 2013-05-21 Revalesio Corporation Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
US10125359B2 (en) 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
US9745567B2 (en) 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
MX337862B (en) * 2008-04-28 2016-03-16 Revalesio Corp Compositions and methods for treating multiple sclerosis.
CA2723215A1 (en) 2008-05-01 2009-11-05 Revalesio Corporation Compositions and methods for treating digestive disorders
US8815292B2 (en) 2009-04-27 2014-08-26 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
KR20130114581A (en) 2010-05-07 2013-10-18 레발레시오 코퍼레이션 Compositions and methods for enhancing physiological performance and recovery time
EP2603202A4 (en) 2010-08-12 2016-06-01 Revalesio Corp Compositions and methods for treatment of taupathy
KR20140020321A (en) * 2011-04-13 2014-02-18 레발레시오 코퍼레이션 Compositions and methods for inhibiting and/or modulating effector t-cells involved in inflammatory neurodegenerative disease
CN102268070B (en) * 2011-07-01 2012-11-28 中国药科大学 Substrate metal prolease-9 polypeptide inhibitor 2 and application thereof
CN102250213B (en) * 2011-07-01 2012-11-07 中国药科大学 Matrix metalloproteinase-9 polypeptide inhibitor 3 and application thereof
CN102268069B (en) * 2011-07-01 2012-11-28 中国药科大学 Substrate metal prolease-9 polypeptide inhibitor 4 and application thereof
KR101492435B1 (en) * 2012-12-28 2015-02-10 고려대학교 산학협력단 COMPOSITION FOR PREVENTING OR TREATING TSLP-MEDIATED DISEASES COMPRISING siRNA AGAINST HIF-1α AS AN ESSENTIAL COMPONENT
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
CN105477628B (en) * 2014-09-19 2021-04-30 山东蓝金生物工程有限公司 Anticancer composition and use thereof
CN106943593A (en) * 2017-03-24 2017-07-14 浙江中医药大学 Application of the anti-TSLP antibody in the chronic itch medicine of preventing and treating is prepared
US11345758B2 (en) 2017-06-27 2022-05-31 Translational Sciences, Inc. Inhibition of vascular matrix metalloproteinase-9 to treat ischemic injury
AU2020279960A1 (en) * 2019-05-17 2021-12-23 The Trustees Of The University Of Pennsylvania Methods and compositions for treating obesity and/or skin disorders
CN114887053A (en) * 2019-11-29 2022-08-12 康诺亚生物医药科技（成都）有限公司 Development and application of TSLP (total stress relaxation) related disease therapeutic agent

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1178952C (en) * 1998-07-28 2004-12-08 加利福尼亚大学董事会 Nucleic acids encoding G-protein coupled receptor involved in sensory transduction
DE60039301D1 (en) * 1999-07-21 2008-08-07 Omeros Corp RINSE SOLUTIONS AND METHODS FOR PAIN-INHIBITING, INFLAMMATION-INHIBITING AND INHIBITION OF CARTILAGE REMOVAL
US20040235732A1 (en) * 2000-11-03 2004-11-25 Qun-Yong Zhou Method for modulating angiogenesis using prokineticin receptor antagonists
US20030232114A1 (en) * 2002-06-13 2003-12-18 Nikola Dekleva Method for liquid enrichment with oxygen and applications of enriched liquids
WO2004022098A1 (en) * 2002-09-09 2004-03-18 Borsos Ferenc Oxygen-enriched water, treated within a magnetic field and heavy water
US20070077553A1 (en) * 2003-10-30 2007-04-05 Rosetta Genomics Bioinformatically detectable group of novel vaccinia regulatory genes and uses thereof
WO2004071436A2 (en) * 2003-02-10 2004-08-26 Thomas Jefferson University The use of gcc ligands
US20090010920A1 (en) * 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US7393924B2 (en) * 2004-01-06 2008-07-01 Franco Vitaliano Smart bio-nanoparticle elements
KR100583430B1 (en) * 2004-03-08 2006-05-24 양경숙 Wheel-exchangeable scooter
US20050249712A1 (en) * 2004-03-23 2005-11-10 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for use of TSLP and agonists and antagonists thereof
WO2008018932A2 (en) * 2006-05-01 2008-02-14 The Board Of Trustees Of The Leland Stanford Junior University Method and use of nano-scale devices for reduction of tissue injury in ischemic and reperfusion injury
US20080014278A1 (en) * 2006-06-30 2008-01-17 Nucryst Pharmaceuticals Metal-containing formulations and methods of use
US8597689B2 (en) * 2006-10-25 2013-12-03 Revalesio Corporation Methods of wound care and treatment
EP2083876A4 (en) * 2006-10-25 2012-09-19 Revalesio Corp Methods of wound care and treatment
US7832920B2 (en) * 2006-10-25 2010-11-16 Revalesio Corporation Mixing device for creating an output mixture by mixing a first material and a second material
EP2215260A4 (en) * 2007-10-25 2011-04-20 Revalesio Corp Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
MX337862B (en) * 2008-04-28 2016-03-16 Revalesio Corp Compositions and methods for treating multiple sclerosis.

Also Published As

Publication number Publication date
JP5688371B2 (en) 2015-03-25
CA2741336A1 (en) 2010-04-29
CN102257130B (en) 2016-07-06
JP5688370B2 (en) 2015-03-25
JP2015044869A (en) 2015-03-12
IL212277A0 (en) 2011-06-30
WO2010048455A1 (en) 2010-04-29
EP2350263A1 (en) 2011-08-03
EP2364154A1 (en) 2011-09-14
BRPI0920201A2 (en) 2019-09-10
JP2012506453A (en) 2012-03-15
CA2741341A1 (en) 2010-04-29
BRPI0920430A2 (en) 2019-09-24
AU2009308362A1 (en) 2010-04-29
JP2015044868A (en) 2015-03-12
MX2011004233A (en) 2011-06-24
IL212309A0 (en) 2011-06-30
MX337035B (en) 2016-02-09
EP2350263A4 (en) 2013-07-03
CN102256607A (en) 2011-11-23
CN102256607B (en) 2014-11-05
JP2012506451A (en) 2012-03-15
AU2009308362B2 (en) 2016-02-04
AU2009308302A1 (en) 2010-04-29
WO2010048425A1 (en) 2010-04-29
MX2011004235A (en) 2011-06-24
EP2364154A4 (en) 2013-07-10
AU2009308302B2 (en) 2016-01-21
CN102257130A (en) 2011-11-23

Similar Documents

Publication Publication Date Title
IL212309A0 (en) Compositions for use in treating matrix metalloproteinase 9 (mmp9)-mediated conditions
HRP20190214T1 (en) Compositions and methods for treating purpura
IL217280B (en) Cannabidiol and compositions containing same for use in treating partial seizures
IL205318A (en) Compositions comprising electrochemically altered aqueous fluids for use in treating inflammation
PL2268612T3 (en) Arylsulfonamide-based matrix metalloprotease inhibitors
GB0719181D0 (en) Stain treating composition
ZA201008295B (en) Improvements in feedwells
EP2120561A4 (en) Compositions for treating biofilms and methods for using same
IL205939A (en) Compounds for use in treating lysosomal disorders
IL210097A0 (en) Compositions and methods for treating unfluenza
GB0801411D0 (en) Improvements in bondwire design
ZA200900140B (en) Methods and compositions for treating biofilms
IL211904A0 (en) Composition for treating disese
GB0725347D0 (en) Improvements in or relating to pipeine pigs
GB2470747B (en) Improvements in valves
GB2457373B (en) Improvements in or relating to radiator assemblies
GB0810407D0 (en) Improvements in platinum compounds
GB0823515D0 (en) Improvements in bivvies
GB0813734D0 (en) Com-fee 2 in 1
GB0807213D0 (en) Visa card dispencer
GB0814242D0 (en) Oil Compositions for use in therapy
GB0910378D0 (en) Oil compositions for use in therapy
GB0816784D0 (en) Composition for use in treating tuberculosis
GB0816548D0 (en) Effect card
SI2341937T1 (en) Composition for treating disease

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees